Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis

Circulation

Volumn 135, Issue 14, 2017, Pages 1357-1377

  Maurer, Mathew S ^a   Elliott, Perry ^b   Comenzo, Raymond ^c   Semigran, Marc ^d   Rapezzi, Claudio ^e  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c TUFTS MEDICAL CENTER   (United States)

^d HARVARD UNIVERSITY   (United States)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

amyloidosis; cardiomyopathies; echocardiography; heart failure, diastolic; immunoglobulin light chains; magnetic resonance imaging; prealbumin; radionuclide imaging

Indexed keywords

AMYLOID; PREALBUMIN; PROTEIN PRECURSOR;

ARTICLE; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL PRACTICE; DELAYED DIAGNOSIS; ECHOGRAPHY; ELECTROCARDIOGRAM; GENE SEQUENCE; HEART AMYLOIDOSIS; HEART TRANSPLANTATION; HUMAN; LABORATORY TEST; MOLECULAR PATHOLOGY; MULTIMODAL IMAGING; MYOCARDIAL PERFUSION IMAGING; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; AGED; AMYLOIDOSIS; CARDIOMYOPATHIES; MIDDLE AGED;

AGED; AMYLOIDOSIS; CARDIOMYOPATHIES; HUMANS; MIDDLE AGED;

EID: 85017002282     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.024438     Document Type: Article

References (147)

1. Glenner GG, Ein D, Eanes ED, Bladen HA, Terry W, Page DL. Creation of "amyloid" fibrils from Bence Jones proteins in vitro. Science. 1971; 174: 712-714.
2. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003; 349: 583-596. doi: 10.1056/NEJMra023144.
3. Kyle RA. Amyloidosis: a convoluted story. Br J Haematol. 2001; 114: 529-538.
4. Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA. Immunoglobulin light chain amyloidosis. Expert Rev Hematol. 2014; 7: 143-156. doi: 10.1586/17474086.2014.858594.
5. Cohen AS, Calkins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature. 1959; 183: 1202-1203.
6. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009; 114: 4957-4959. doi: 10.1182/blood-2009-07-230722.
7. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009; 120: 1203-1212. doi: 10.1161/CIRCULATIONAHA.108.843334.
8. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM, Kurland LT. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992; 79: 1817-1822.
9. Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, Dungu J, Banypersad SM, Wechalekar AD, Whelan CJ, Hawkins PN, Gillmore JD. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013; 161: 525-532. doi: 10.1111/bjh.12286.
10. Hemminki K, Li X, Färsti A, Sundquist J, Sundquist K. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health. 2012; 12: 974. doi: 10.1186/1471-2458-12-974.
11. Muchtar E, Buadi FK, Dispenzieri A, Gertz MA. Immunoglobulin light-chain amyloidosis: from basics to new developments in diagnosis, prognosis and therapy. Acta Haematol. 2016; 135: 172-190. doi: 10.1159/000443200.
12. Galat A, Guellich A, Bodez D, Slama M, Dijos M, Zeitoun DM, Milleron O, Attias D, Dubois-Randé JL, Mohty D, Audureau E, Teiger E, Rosso J, Monin JL, Damy T. Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart J. 2016; 37: 3525-3531. doi: 10.1093/eurheartj/ehw033.
13. Maurer MS. Noninvasive identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology. Am J Med. 2015; 128: 1275-1280. doi: 10.1016/j.amjmed.2015.05.039.
14. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008; 40: 232-239. doi: 10.1080/07853890701842988.
15. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014; 2: 113-122. doi: 10.1016/j.jchf.2013.11.004.
16. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016; 387: 2641-2654. doi: 10.1016/S0140-6736(15)01274-X.
17. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P. Wild-Type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015; 36: 2585-2594. doi: 10.1093/eurheartj/ehv338.
18. Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015; 22: 171-174. doi: 10.3109/13506129.2015.1051219.
19. Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH, Butler KR, Boerwinkle E, Solomon SD. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015; 372: 21-29. doi: 10.1056/NEJMoa1404852.
20. Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Adv Ther. 2015; 32: 920-928. doi: 10.1007/s12325-015-0250-0.
21. Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Planté-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C. THAOS Investigators. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016; 68: 161-172. doi: 10.1016/j.jacc.2016.03.596.
22. Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-Type transthyretin amyloidosis. Curr Med Res Opin. 2013; 29: 63-76. doi: 10.1185/03007995.2012.754348.
23. Arvidsson S, Pilebro B, Westermark P, Lindqvist P, Suhr OB. Amyloid cardiomyopathy in hereditary transthyretin V30M amyloidosis- impact of sex and amyloid fibril composition. PLoS One. 2015; 10: e0143456. doi: 10.1371/journal.pone.0143456.
24. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Long-Term follow-up from a phase . study of singleagent bortezomib in relapsed systemic AL amyloidosis. Blood. 2014; 124: 2498-2506. doi: 10.1182/blood-2014-04-568329.
25. Comenzo RL, Wally J, Kica G, Murray J, Ericsson T, Skinner M, Zhang Y. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. Br J Haematol. 1999; 106: 744-751.
26. Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001; 98: 714-720.
27. Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chainassociated amyloidosis (AL). Blood. 2003; 101: 3801-3808. doi: 10.1182/blood-2002-09-2707.
28. Bodi K, Prokaeva T, Spencer B, Eberhard M, Connors LH, Seldin DC. AL-Base: a visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences. Amyloid. 2009; 16: 1-8. doi: 10.1080/13506120802676781.
29. Perfetti V, Palladini G, Casarini S, Navazza V, Rognoni P, Obici L, Invernizzi R, Perlini S, Klersy C, Merlini G. The repertoire of light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood. 2012; 119: 144-150. doi: 10.1182/blood-2011-05-355784.
30. Weiss BM, Wong SW, Comenzo RL. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis. Blood. 2016; 127: 2275-2280. doi: 10.1182/blood-2015-11-681650.
31. Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M, Grigioni F, Leone O, Cappelli F, Palladini G, Rimessi P, Ferlini A, Arpesella G, Pinna AD, Merlini G, Perlini S. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013; 34: 520-528. doi: 10.1093/eurheartj/ehs123.
32. Svendsen IH, Steensgaard-Hansen F, Nordvåg BY. A clinical, echocardiographic and genetic characterization of a Danish kindred with familial amyloid transthyretin methionine 111 linked cardiomyopathy. Eur Heart J. 1998; 19: 782-789.
33. Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, Rowczenio D, Pflugfelder PW, Fox Z, Lachmann HJ, Wechalekar AD, Hawkins PN, Gillmore JD. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012; 33: 1120-1127. doi: 10.1093/eurheartj/ehr383.
34. Maurer MS HM, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ. Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Planté-Bordeneuve V, Coelho R, Mundayat R, Suhr OB, Waddington Cruz M, C. Rapezzi on behalf of THAOS Investigators. Genotype and phenotype of transthyretin-related cardiac amyloidosis in the united states: a report from the Transthyretin Amyloid Outcome Survey (THAOS). JACC 2016; 68: 161-72.
35. Kyle RA, Spittell PC, Gertz MA, Li CY, Edwards WD, Olson LJ, Thibodeau SN. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med. 1996; 101: 395-400. doi: 10.1016/S0002-9343(96)00229-X.
36. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-Associated amyloidosis. Arch Intern Med. 2005; 165: 1425-1429. doi: 10.1001/archinte.165.12.1425.
37. Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, Berk JL, Seldin DC. Heart failure resulting from age-related cardiac amyloid disease associated with wild-Type transthyretin: a prospective, observational cohort study. Circulation. 2016; 133: 282-290. doi: 10.1161/CIRCULATIONAHA.115.018852.
38. Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan DR. Prospective evaluation of the morbidity and mortality of wildtype and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012; 164: 222-228.e1. doi: 10.1016/j.ahj.2012.04.015.
39. Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013; 2: e000098. doi: 10.1161/JAHA.113.000098.
40. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A. Natural history of wild-Type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016; 68: 1014-1020. doi: 10.1016/j.jacc.2016.06.033.
41. Nakagawa M, Sekijima Y, Yazaki M, Tojo K, Yoshinaga T, Doden T, Koyama J, Yanagisawa S, Ikeda S. Carpal tunnel syndrome: a common initial symptom of systemic wild-Type ATTR (ATTRwt) amyloidosis. Amyloid. 2016; 23: 58-63. doi: 10.3109/13506129.2015.1135792.
42. Givens RC, Russo C, Green P, Maurer MS. Comparison of cardiac amyloidosis due to wild-Type and V122I transthyretin in older adults referred to an academic medical center. Aging Health. 2013; 9: 229-235. doi: 10.2217/ahe.13.10.
43. Bhuiyan T, Helmke S, Patel AR, Ruberg FL, Packman J, Cheung K, Grogan D, Maurer MS. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-Type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS). Circ Heart Fail. 2011; 4: 121-128. doi: 10.1161/CIRCHEARTFAILURE.109.910455.
44. Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014; 114: 1089-1093. doi: 10.1016/j.amjcard.2014.07.026.
45. Mussinelli R, Salinaro F, Alogna A, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G, Perlini S. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol. 2013; 18: 271-280. doi: 10.1111/anec.12036.
46. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982; 49: 9-13.
47. Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, Gagliardi C, Milandri A, Rapezzi C, Falk RH. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014; 129: 1840-1849. doi: 10.1161/CIRCULATIONAHA.113.006242.
48. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010; 375: 1721-1728. doi: 10.1016/S0140-6736(10)60482-5.
49. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002; 346: 1786-1791. doi: 10.1056/NEJMoa013354.
50. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, Cockwell P. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3: 1684-1690. doi: 10.2215/CJN.02290508.
51. Masuda M, Ishimura E, Ochi A, Tsujimoto Y, Tahahra H, Okuno S, Tabata T, Nishizawa Y, Inaba M. Serum β2-microglobulin correlates positively with left ventricular hypertrophy in long-Term hemodialysis patients. Nephron Clin Pract. 2014; 128: 101-106. doi: 10.1159/000365447.
52. Noël LH, Zingraff J, Bardin T, Atienza C, Kuntz D, Drüeke T. Tissue distribution of dialysis amyloidosis. Clin Nephrol. 1987; 27: 175-178.
53. Perfetto F, Bergesio F, Grifoni E, Fabbri A, Ciuti G, Frusconi S, Angelotti P, Spini V, Cappelli F. Different NT-proBNP circulating levels for different types of cardiac amyloidosis. J Cardiovasc Med (Hagerstown). 2016; 17: 810-817. doi: 10.2459/JCM.0000000000000349.
54. Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, Sawyer DB, Semigran MJ, Macgillivray TE, Seldin DC, Falk R, Liao R. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A. 2010; 107: 4188-4193. doi: 10.1073/pnas.0912263107.
55. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, Apstein CS, Liao R. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004; 94: 1008-1010. doi: 10.1161/01. RES.0000126569.75419.74.
56. Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, Falk RH, Apstein CS. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001; 104: 1594-1597.
57. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012; 30: 989-995. doi: 10.1200/JCO.2011.38.5724.
58. Dietrich S, Schänland SO, Benner A, Bochtler T, Kristen AV, Beimler J, Hund E, Zorn M, Goldschmidt H, Ho AD, Hegenbart U. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood. 2010; 116: 522-528. doi: 10.1182/blood-2009-11-253237.
59. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012; 26: 2317-2325. doi: 10.1038/leu.2012.100.
60. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schänland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012; 30: 4541-4549. doi: 10.1200/JCO.2011.37.7614.
61. Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, Maurer MS, Sanchorawala V, Wechalekar A, Palladini G, Comenzo RL. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 2016; 30: 1979-1986. doi: 10.1038/leu.2016.191.
62. Damy T, Maurer MS, Rapezzi C, Planté-Bordeneuve V, Karayal ON, Mundayat R, Suhr OB, Kristen AV. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart. 2016; 3: e000289. doi: 10.1136/openhrt-2015-000289.
63. Rapezzi C, Lorenzini M, Longhi S, Milandri A, Gagliardi C, Bartolomei I, Salvi F, Maurer MS. Cardiac amyloidosis: the great pretender. Heart Fail Rev. 2015; 20: 117-124. doi: 10.1007/s10741-015-9480-0.
64. Koyama J, Ikeda S, Ikeda U. Echocardiographic assessment of the cardiac amyloidoses. Circ J. 2015; 79: 721-734. doi: 10.1253/circj.CJ-14-1425.
65. Klein AL, Hatle LK, Burstow DJ, Seward JB, Kyle RA, Bailey KR, Luscher TF, Gertz MA, Tajik AJ. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1989; 13: 1017-1026.
66. Klein AL, Hatle LK, Burstow DJ, Taliercio CP, Seward JB, Kyle RA, Bailey KR, Gertz MA, Tajik AJ. Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1990; 15: 99-108.
67. Liu D, Niemann M, Hu K, Herrmann S, Stärk S, Knop S, Ertl G, Weidemann F. Echocardiographic evaluation of systolic and diastolic function in patients with cardiac amyloidosis. Am J Cardiol. 2011; 108: 591-598. doi: 10.1016/j.amjcard.2011.03.092.
68. Di Bella G, Minutoli F, Pingitore A, Zito C, Mazzeo A, Aquaro GD, Di Leo R, Recupero A, Stancanelli C, Baldari S, Vita G, Carerj S. Endocardial and epicardial deformations in cardiac amyloidosis and hypertrophic cardiomyopathy. Circ J. 2011; 75: 1200-1208.
69. Phelan D, Thavendiranathan P, Popovic Z, Collier P, Griffin B, Thomas JD, Marwick TH. Application of a parametric display of two-dimensional speckle-Tracking longitudinal strain to improve the etiologic diagnosis of mild to moderate left ventricular hypertrophy. J Am Soc Echocardiogr. 2014; 27: 888-895. doi: 10.1016/j.echo.2014.04.015.
70. Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, Radu C, Guendouz S, Couetil JP, Benhaiem N, Hittinger L, Dubois-Randé JL, Plante-Bordeneuve V, Mohty D, Deux JF, Damy T. Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. JACC Cardiovasc Imaging. 2016; 9: 126-138. doi: 10.1016/j.jcmg.2015.05.014.
71. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003; 107: 2446-2452. doi: 10.1161/01. CIR.0000068313.67758.4F.
72. Senapati A, Sperry BW, Grodin JL, Kusunose K, Thavendiranathan P, Jaber W, Collier P, Hanna M, Popovic ZB, Phelan D. Prognostic implication of relative regional strain ratio in cardiac amyloidosis. Heart. 2016; 102: 748-754. doi: 10.1136/heartjnl-2015-308657.
73. Fontana M, Chung R, Hawkins PN, Moon JC. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev. 2015; 20: 133-144. doi: 10.1007/s10741-014-9470-7.
74. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005; 111: 186-193. doi: 10.1161/01.CIR. 0000152819.97857.9D.
75. Ruberg FL, Appelbaum E, Davidoff R, Ozonoff A, Kissinger KV, Harrigan C, Skinner M, Manning WJ. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol. 2009; 103: 544-549. doi: 10.1016/j.amjcard.2008.09.105.
76. Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013; 6: 488-497. doi: 10.1016/j.jcmg.2012.11.013.
77. Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, Castelletti S, Piechnik SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014; 7: 157-165. doi: 10.1016/j.jcmg.2013.10.008.
78. Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014; 7: 133-142. doi: 10.1016/j.jcmg.2013.08.015.
79. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010; 3: 155-164. doi: 10.1016/j.jcmg.2009.09.023.
80. Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadoliniumdelayed hyperenhancement. Magn Reson Med. 2002; 47: 372-383.
81. Wizenberg TA, Muz J, Sohn YH, Samlowski W, Weissler AM. Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. Am Heart J. 1982; 103(4 pt 1): 468-473.
82. Falk RH, Lee VW, Rubinow A, Hood WB Jr, Cohen AS. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol. 1983; 51: 826-830.
83. Gertz MA, Brown ML, Hauser MF, Kyle RA. Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med. 1987; 147: 1039-1044.
84. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005; 46: 1076-1084. doi: 10.1016/j.jacc.2005.05.073.
85. Rapezzi C, Guidalotti P, Salvi F, Riva L, Perugini E. Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. J Am Coll Cardiol. 2008; 51: 1509-1510; author reply 1510. doi: 10.1016/j.jacc.2007.12.038.
86. Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, Ferlini A, Salvi F, Gallo P, Gagliardi C, Branzi A. Usefulness and limitations of 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011; 38: 470-478. doi: 10.1007/s00259-010-1642-7.
87. Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, Lane T, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD. Utility and limitations of 3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014; 15: 1289-1298. doi: 10.1093/ehjci/jeu107.
88. Park MA, Padera RF, Belanger A, Dubey S, Hwang DH, Veeranna V, Falk RH, Di Carli MF, Dorbala S. 18F-Florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study. Circ Cardiovasc Imaging. 2015; 8; e002954.
89. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016; 133: 2404-2412. doi: 10.1161/CIRCULATIONAHA.116.021612.
90. Fine NM, Arruda-Olson AM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kyle RA, Swiecicki PL, Scott CG, Grogan M. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014; 113: 1723-1727. doi: 10.1016/j.amjcard.2014.02.030.
91. Satoskar AA, Efebera Y, Hasan A, Brodsky S, Nadasdy G, Dogan A, Nadasdy T. Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing. Am J Surg Pathol. 2011; 35: 1685-1690. doi: 10.1097/PAS.0b013e3182263d74.
92. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016; 387: 2641-2654. doi: 10.1016/S0140-6736(15)01274-X.
93. Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, Kimmich C, Goldschmidt H, Ho AD, Hose D, Jauch A, Schänland SO. Translocation t(11; 14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015; 33: 1371-1378. doi: 10.1200/JCO.2014.57.4947.
94. Bochtler T, Hegenbart U, Kunz C, Benner A, Seckinger A, Dietrich S, Granzow M, Neben K, Goldschmidt H, Ho AD, Hose D, Jauch A, Schänland SO. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid. 2014; 21: 9-17. doi: 10.3109/13506129.2013.854766.
95. Bochtler T, Hegenbart U, Kunz C, Benner A, Schänland SO. Reply to R. Warsame, et al. J Clin Oncol. 2015; 33: 3976-3977. doi: 10.1200/JCO.2015.63.2141.
96. Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Ketterling RP, Lin Y, Russell S, Hwa L, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Dispenzieri A. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J. 2015; 5: e310. doi: 10.1038/bcj.2015.34.
97. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006; 108: 2520-2530. doi: 10.1182/blood-2006-03-001164.
98. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011; 29: 1924-1933. doi: 10.1200/JCO.2010.32.2271.
99. Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev. 2012; 26: 137-154. doi: 10.1016/j.blre.2012.03.001.
100. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-Term results in a series of 421 patients. Blood. 2011; 118: 4346-4352. doi: 10.1182/blood-2011-01-330738.
101. Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, Macro M, Pellegrin JL, Lazaro E, Mohty D, Mercie P, Decaux O, Gillmore J, Lavergne D, Bridoux F, Wechalekar AD, Venner CP. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014; 99: 1479-1485. doi: 10.3324/haematol.2014.104109.
102. Langer AL, Miao S, Mapara M, Radhakrishnan J, Maurer MS, Raza S, Mears JG, Solomon A, Lentzsch S. Results of phase I study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Blood. 2015; 126: 188-188.
103. Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, Fontana M, Moon JC, Pinzani M, Gillmore JD, Hawkins PN, Pepys MB. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015; 373: 1106-1114. doi: 10.1056/NEJMoa1504942.
104. Comenzo RL. Out, Out-making amyloid's candle briefer. N Engl J Med. 2015; 373: 1167-1169. doi: 10.1056/NEJMe1508746.
105. Gertz MA LH, Comenzo RL, et al. Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction. J Clin Oncol. 2015; 33: 8514a.
106. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005; 79: 319-328. doi: 10.1002/ajh.20381.
107. Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, Vidus Rosin M, Albertini R, Moratti R, Merlini G, Schänland S. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014; 124: 2325-2332. doi: 10.1182/blood-2014-04-570010.
108. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013; 121: 5124-5130. doi: 10.1182/blood-2013-01-453001.
109. Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program. 2010; 2010: 287-294. doi: 10.1182/asheducation-2010.1.287.
110. Shah G, Kaul E, Fallo S, Cossor F, Smith H, Sprague K, Klein A, Miller K, Comenzo R. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients. Clin Ther. 2013; 35: 1614-1620. doi: 10.1016/j.clinthera.2013.08.015.
111. Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, Basset M, Hawkins P, Merlini G, Wechalekar AD. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015; 126: 612-615. doi: 10.1182/blood-2015-01-620302.
112. Kuhn DJ, Orlowski RZ, Bjorklund CC. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets. 2011; 11: 285-295.
113. Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C, Bello C, Hoover E, Riedel E, Giralt S, Comenzo RL. Bortezomib and dexamethasone consolidation following risk-Adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia. 2013; 27: 823-828. doi: 10.1038/leu.2012.274.
114. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-Adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007; 109: 457-464. doi: 10.1182/blood-2006-07-035352.
115. Palladini G, Russo P, Nuvolone M, Lavatelli F, Perfetti V, Obici L, Merlini G. Treatment with oral melphalan plus dexamethasone produces long-Term remissions in AL amyloidosis. Blood. 2007; 110: 787-788. doi: 10.1182/blood-2007-02-076034.
116. Castaño A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015; 20: 163-178. doi: 10.1007/s10741-014-9462-7.
117. Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015; 47: 625-638. doi: 10.3109/07853890.2015.1068949.
118. Dubrey S, Ackermann E, Gillmore J. The transthyretin amyloidoses: advances in therapy. Postgrad Med J. 2015; 91: 439-448. doi: 10.1136/postgradmedj-2014-133224.
119. Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, Furtado E, Barroso E, Daniel J, Samuel D, Adam R, Karam V, Poterucha J, Lewis D, Ferraz-Neto BH, Cruz MW, Munar-Ques M, Fabregat J, Ikeda S, Ando Y, Heaton N, Otto G, Suhr O. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015; 99: 1847-1854. doi: 10.1097/TP.0000000000000574.
120. Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med. 2005; 352: 2356. doi: 10.1056/NEJM200506023522219.
121. Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB. Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation. 2012; 93: 1017-1023. doi: 10.1097/TP.0b013e31824b3749.
122. Niemietz C, Chandhok G, Schmidt H. Therapeutic oligonucleotides targeting liver disease: TTR amyloidosis. Molecules. 2015; 20: 17944-17975. doi: 10.3390/molecules201017944.
123. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, Suhr OB. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013; 369: 819-829. doi: 10.1056/NEJMoa1208760.
124. Ackermann EJ, Guo S, Booten S, Alvarado L, Benson M, Hughes S, Monia BP. Clinical development of an antisense therapy for the treatment of transthyretin-Associated polyneuropathy. Amyloid. 2012; 19(suppl 1): 43-44. doi: 10.3109/13506129.2012.673140.
125. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ. Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013; 310: 2658-2667. doi: 10.1001/jama.2013.283815.
126. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceição IM, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Wilson A, Grogan DR. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012; 79: 785-792. doi: 10.1212/WNL.0b013e3182661eb1.
127. Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudinière R. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012; 109: 9629-9634. doi: 10.1073/pnas.1121005109.
128. Ward JE, Ren R, Toraldo G, Soohoo P, Guan J, O'Hara C, Jasuja R, Trinkaus-Randall V, Liao R, Connors LH, Seldin DC. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011; 118: 6610-6617. doi: 10.1182/blood-2011-04-351643.
129. Obici L, Cortese A, Lozza A, Palladini G, Perlini S, Gobbi M, Obici L, Cortese A, Lozza A, Palladini G, Perlini S, Gobbi M, Saraiva MJ, Merlini G. A phase II study of doxycycline plus tauroursodeoxycholic acid in transthyretin amyloidosis. Paper presented at: XIVth International Symposium on Amyloidosis (ISA); April 27 to May 1, 2014; Indianapolis, IN. In Amyloid: Insoluble, but Solvable. Proceedings of the XIVth International Symposium on Amyloidosis. Oral Presentation 68; pp 87-88.
130. Kristen AV, Lehrke S, Buss S, Mereles D, Steen H, Ehlermann P, Hardt S, Giannitsis E, Schreiner R, Haberkorn U, Schnabel PA, Linke RP, Räcken C, Wanker EE, Dengler TJ, Altland K, Katus HA. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol. 2012; 101: 805-813. doi: 10.1007/s00392-012-0463-z.
131. aus dem Siepen F, Bauer R, Aurich M, Buss SJ, Steen H, Altland K, Katus HA, Kristen AV. Green tea extract as a treatment for patients with wild-Type transthyretin amyloidosis: an observational study. Drug Des Devel Ther. 2015; 9: 6319-6325. doi: 10.2147/DDDT. S96893.
132. Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, Conceiçao I, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Grogan DR. Long-Term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013; 260: 2802-2814. doi: 10.1007/s00415-013-7051-7.
133. Quarta CC, Falk RH, Solomon SD, Suhr OB, Obici L, Perlini S, Lindqvist P, Koyama J, Sekijima Y, Zeldenrust SR, Yamashita T, Horibata Y, Miller F, Gorevic P, Merlini G, Ando Y, Ikeda S, Ruberg F, Berk JL. The prevalence of cardiac amyloidosis in familial amyloidotic polyneuropathy with predominant neuropathy: The Diflunisal Trial. XIVth International Symposium on Amyloidosis. 2014: 88-89.
134. Lozeron P, Théaudin M, Mincheva Z, Ducot B, Lacroix C, Adams D. French Network for FAP (CORNAMYL). Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2013; 20: 1539-1545. doi: 10.1111/ene.12225.
135. Cho Y, Baranczak A, Helmke S, Teruya S, Horn EM, Maurer MS, Kelly JW. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-Type transthyretin amyloidosis (cardiomyopathy). Amyloid. 2015; 22: 175-180. doi: 10.3109/13506129.2015.1063485.
136. Hosenpud JD, DeMarco T, Frazier OH, Griffith BP, Uretsky BF, Menkis AH, O'Connell JB, Olivari MT, Valantine HA. Progression of systemic disease and reduced long-Term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation. 1991; 84(5 suppl): III338-III343.
137. Maurer MS, Raina A, Hesdorffer C, Bijou R, Colombo P, Deng M, Drusin R, Haythe J, Horn E, Lee SH, Marboe C, Naka Y, Schulman L, Scully B, Shapiro P, Prager K, Radhakrishnan J, Restaino S, Mancini D. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation. 2007; 83: 539-545. doi: 10.1097/01. tp.0000255567.80203.bd
138. Dey BR, Chung SS, Spitzer TR, Zheng H, Macgillivray TE, Seldin DC, McAfee S, Ballen K, Attar E, Wang T, Shin J, Newton-Cheh C, Moore S, Sanchorawala V, Skinner M, Madsen JC, Semigran MJ. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 2010; 90: 905-911. doi: 10.1097/TP.0b013e3181f10edb
139. Davis MK, Kale P, Liedtke M, Schrier S, Arai S, Wheeler M, Lafayette R, Coakley T, Witteles RM. Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Am J Transplant. 2015; 15: 650-658. doi: 10.1111/ajt.13025.
140. Davis MK, Lee PH, Witteles RM. Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant. 2015; 34: 658-666. doi: 10.1016/j.healun.2014.09.006.
141. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, Danziger-Isakov L, Kirklin JK, Kirk R, Kushwaha SS, Lund LH, Potena L, Ross HJ, Taylor DO, Verschuuren EA, Zuckermann A. International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases Council; International Society for Heart Lung Transplantation (ISHLT) Pediatric Transplantation Council; International Society for Heart Lung Transplantation (ISHLT) Heart Failure and Transplantation Council. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016; 35: 1-23. doi: 10.1016/j.healun.2015.10.023.
142. Gilstrap L NE, Maurer M, Feltrin G, Estep J, Witteles R, Zucker M, Baran D, Kushwaha S, Seldin D, Semigran M. Multi-center, international registry of cardiac transplantation for light chain (AL) and transthyreitin (TTR) amyloidosis, A [abstract]. Am J Transplant 2013; 13 (suppl 5): 130.
143. Niehaus E, Gilstrap L, Maurer MS, Witteles R, Zucker M, Baran D, Estep J, Feltrin G, Stone JR, Patel J, Seldin D, Semigran M. Outcomes from an international registry of cardiac transplantation for light chain (AL) and transthyreitin (TTR) amyloidosis. XIVth International Symposium on Amyloidosis. 2014. In Amyloid: Insoluble, but Solvable. Proceedings of the XIVth International Symposium on Amyloidosis. Oral Presentation 78; pp 96-97.
144. Topilsky Y, Pereira NL, Shah DK, Boilson B, Schirger JA, Kushwaha SS, Joyce LD, Park SJ. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Heart Fail. 2011; 4: 266-275. doi: 10.1161/CIRCHEARTFAILURE.110.959288.
145. Grupper A, Park SJ, Pereira NL, Schettle SD, Gerber Y, Topilsky Y, Edwards BS, Daly RC, Stulak JM, Joyce LD, Kushwaha SS. Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease. J Heart Lung Transplant. 2015; 34: 1042-1049. doi: 10.1016/j.healun.2015.03.012.
146. Tabtabai S, Steiner J, Vaduganathan M, Stone J, Estep J, Witteles R, Giuseppe F, Zucker M, Baran D, Seldin D, Patel J, Hanna M, Cordero-Reyes A, Selby V, Maurer M, Semigran MJ. The use of circulatory support while awaiting heart transplant in patients with AL and TTR: amyloidosis: a report from iCCAT, the International Consortium for Cardiac Amyloid Transplant. J Heart Lung Transplant. 2015; 34: S95-S96.
147. Burkhoff D, Maurer MS, Joseph SM, Rogers JG, Birati EY, Rame JE, Shah SJ. Left atrial decompression pump for severe heart failure with preserved ejection fraction: theoretical and clinical considerations. JACC Heart Fail. 2015; 3: 275-282. doi: 10.1016/j.jchf.2014.10.011.